Myelodysplastic syndromes
A group of blood cancers in which the bone marrow makes blood cells that do not grow into healthy ones. Too few healthy blood cells can lead to infection, anaemia or easy bleeding. Treatment ranges from blood transfusions and medicines to strong chemotherapy with a stem cell transplant, which can cure some people. It is rare and more likely after age 60, or after chemotherapy or radiotherapy for another cancer.
Read more about myelodysplastic syndromesSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Trial-stage treatments and research studies you can join
Filters
- Bexmarilimab With Azacitidine for Higher-Risk Myelodysplastic Syndromes
Tests bexmarilimab with azacitidine in adults newly diagnosed with higher-risk myelodysplastic syndromes.
Alessandria, ItalyAlso Bologna, Candiolo, MilanAge 18+ - Study of how the body absorbs ziftomenib in relapsed or hard-to-treat AML or MDS
Tests how the body absorbs ziftomenib in adults with relapsed or unresponsive leukemia.
Bologna, ItalyAlso RavennaAge 18+ - Tests elritercept in adults with myelodysplastic syndromes needing regular blood transfusions
Tests elritercept against placebo in adults with low-risk myelodysplastic syndromes needing transfusions.
Ancona, ItalyAlso Candiolo, Florence, Milan, Pavia, Reggio Calabria, Rome, Rozzano, TurinAge 18+ - Elritercept Compared With Epoetin Alfa for Anemia in Lower Risk Myelodysplastic Syndromes
Compares elritercept with epoetin alfa for anemia in adults with myelodysplastic syndrome needing transfusions.
Bologna, ItalyAlso Candiolo, Florence, Milan, Naples, Novara, Padova, Pavia, Rome, …Age 18+ - First test of GEN3018 in adults with returned or resistant acute myeloid leukemia
Tests the antibody GEN3018 for safety in adults with returned blood cancers.
Bergamo, ItalyAlso Pisa, RozzanoAge 18+ - Tests AZD3632 alone or with other drugs in advanced blood cancers
Tests the oral drug AZD3632 in adults with advanced leukemia or myelodysplastic syndromes.
Bologna, ItalyAlso RavennaAge 16+ - Tests pacritinib in adults with VEXAS syndrome, a rare inflammatory disease
Tests pacritinib against placebo in adults with VEXAS syndrome, an inflammatory condition.
Milan, ItalyAlso Padova, Reggio Emilia, RomaAge 18+ - Tests lisaftoclax with azacitidine for newly diagnosed higher-risk myelodysplastic syndrome
Tests lisaftoclax plus azacitidine against placebo in adults with newly diagnosed higher-risk myelodysplastic syndrome.
Candiolo, ItalyAlso Ferrara, Florence, Meldola, Milan, Novara, Ravenna, Rome, Rozzano, …Age 18+ - Tests oral ASTX030 alone or with venetoclax in myeloid blood cancers
Tests an oral form of azacitidine, alone or with venetoclax, in adults with blood cancers.
Bologna, ItalyAlso Florence, Milan, Novara, Ravenna, Rome, TurinAge 18+ - Tests luspatercept with Eprex in low-risk myelodysplastic syndrome patients
Tests luspatercept combined with Eprex in adults with low-risk myelodysplastic syndrome.
Candiolo, ItalyAge 18+ - Continued RVU120 Treatment for Patients From an Earlier Study
Gives continued RVU120 treatment to adults from an earlier RVU120 study.
Bari, ItalyAge 18+ - Tests bezuclastinib in adults with advanced systemic mastocytosis
Tests bezuclastinib in adults with advanced systemic mastocytosis, a rare blood disease.
Bologna, ItalyAlso Florence, Salerno, VeronaAge 18+ - Tests BGB-11417 alone or with azacitidine in myeloid blood cancers
Tests BGB-11417, alone or with azacitidine, in adults with acute myeloid leukemia or MDS.
Bologna, ItalyAlso Meldola, MilanAge 18+ - Compares ivosidenib and azacitidine in people with IDH1-mutated myelodysplastic syndromes
Compares two treatments in adults with myelodysplastic syndromes who have an IDH1 gene change.
Ancona, ItalyAlso Bologna, Florence, Pavia, Rome, Rozzano, TurinAge 18+ - Continued ASTX727 treatment for people from earlier studies with blood cancers
Gives continued ASTX727 to adults with blood cancers who benefited from earlier studies.
Milan, ItalyAge 18+ - Testing S241656 alone or with other drugs in certain blood cancers
Tests S241656 for safety in adults with relapsed or hard-to-treat myeloid leukemias.
Bologna, ItalyAlso Naples, Padova, Pavia, RozzanoAge 18+ - Long-term safety of luspatercept in people from earlier luspatercept studies
Continues luspatercept treatment and follow-up in adults with anemia-related blood disorders.
Bologna, ItalyAlso Brindisi, Cagliari, Ferrara, Florence, Genoa, Lecce, Milan, Modena, …Age 18+ - Testing momelotinib for anemia caused by low-risk myelodysplastic syndrome
Tests momelotinib, at different doses, in adults with low-risk myelodysplastic syndrome and anemia.
Catania, ItalyAlso Florence, Milan, Orbassano, Rozzano, UdineAge 18+ - Tests enzomenib in people with acute leukemia or related blood cancers
Tests enzomenib, a new drug, in people 12 and older with acute leukemia.
Bologna, ItalyAlso Busto Arsizio, Genoa, Meldola, Padua, Perugia, Ravenna, Rome, TurinAge 12+ - Tests SP-420 for removing iron from organs in certain blood disorders
Tests SP-420 to remove excess iron in adults with thalassemia or myelodysplastic syndrome.
Bologna, ItalyAlso Cagliari, Florence, Genoa, Milan, Modena, Naples, PaviaAge 18 to 64
Trials that have ended are not listed here, because nobody can join them. Stopped and finished Myelodysplastic syndromes trials (research view)
Where treatment stands
Some patients can be cured with strong chemotherapy and a stem cell transplant from a donor. For others, treatment may slow the disease from getting worse.
In the EU, imetelstat and efbemalenograstim alfa were first approved in 2025 and 2024, not always for this disease.
Approved: 13
Officially approved for this disease in the EU, the US, Switzerland or France.
Human testing stage: 11
Being tested in people. Many treatments at this stage are never approved.
Animal testing stage: 3
Worked in animals in a study published in the last 12 months. Most treatments at this stage never reach people.
Placebo: a dummy treatment without the medicine, used for comparison.
Phase 1, 2, 3: the steps of testing in people. Phase 1 checks safety, phase 3 is the last step before approval.
The EU medicines agency (EMA) and its list of medicines in the EU, US prescribing labels (DailyMed, openFDA), the Swiss medicines register (Swissmedic), the French medicines database (ANSM) and the Health Canada drug database, checked on 11 November 2026. Every medicine links to its own official text.
A computer made this list from the official texts: it kept only medicines whose own approval text names the disease, wrote "Who it is for" from that text and checked it against the text a second time. People have not reviewed it yet.
The trials: ClinicalTrials.gov and the EU trials register, as copied into our trial database, checked on 12 November 2026. Every treatment in trials links to its own trial records; the texts are written by AI from them and checked against them by a second AI. People have not reviewed them yet. Placebo, standard medicines used for comparison and procedures are left out.
Phase 3 trials are listed from every country; only some phase 2 trials are listed, so 128 other open phase 2 trials are not listed.
Animal and lab research: studies listed in PubMed and published in the 12 months before 12 November 2026, found by a search for myelodysplastic syndromes. AI chose the treatments from the study summaries and wrote the texts; a second AI checked each one against its study summary. People have not reviewed them yet. Treatments already in the approved or human testing lists are left out. A result in animals or cells does not show that a treatment works in people.
Not medical advice. Talk to your doctor before you change any treatment.
The approval records under a medicine come from Drugs@FDA and the FDA labels (openFDA) and from the EU medicines agency’s medicine data, with its orphan designations, checked on 13 Nov 2026. A date is the medicine’s first approval, for any use; the quoted text is its approved use as written today.
Support organisations
Patient organisations and helplines in Italy, for you and your family.
Myelodysplastic syndromes organisations in Italy
- AIL - Associazione Italiana contro le Leucemie, Linfomi e Mieloma
Italian blood-cancer association with local sections near haematology centres: patient and family support, home care, AIL patient houses near treatment centres, free haematology helpline.
- Associazione Italiana Pazienti con Sindrome Mielodisplastica (AIPaSiM)
Italian patient association for people with myelodysplastic syndromes. Member of MDS Alliance.
- Lega Italiana per la Lotta contro i Tumori (LILT)
Italian national cancer league (ECL member) focused on prevention, early diagnosis and support for cancer patients through its provincial associations.
General support in Italy
- Telefono Amico Italia
Italian volunteer emotional support service since 1967, listening to anyone in crisis or loneliness by phone (02 2327 2327), chat and WhatsApp.
International organisations
- Aplastic Anemia and MDS International Foundation
Foundation supporting patients and families with aplastic anemia, MDS and related bone marrow failure diseases.
- DKMS
Finds blood stem cell donors worldwide so that people with blood cancer can have a transplant.
- MDS Foundation
US-based global nonprofit supporting patients with MDS and related diseases such as AML, their families and providers, with education, resources and support.
Offer tissue or data
There are three ways to help research move faster.
Approved treatments
17 medicines are approved for myelodysplastic syndromes in at least one of the places we checked. An approval in one place does not mean the medicine is offered or paid for where you live.
Checked on 11 Nov 2026 in the official lists of the US (FDA), the EU (EMA), Japan (PMDA, approvals since April 2004), Switzerland (Swissmedic), France (ANSM, medicines approved in France only) and Taiwan (TFDA). For Canada (Health Canada) and Singapore (HSA) we checked only whether a medicine is sold there, not what for. 6 uncertain matches are left out. Other countries' own approvals were not checked.
“Miracle cure” fact checker
Social media spreads misinformation. Paste here what you read, and we'll tell you whether there is scientific evidence behind it.
What you paste is checked with AI (Anthropic, USA) and is not stored. Please leave out names and other personal details.
Before you pay for anything, ask three things
- Is there a published study in people?
- Can I have the full price in writing?
- What does my doctor say?
“Cures” others already fact-checked
- CBD (cannabidiol) & Myelodysplastic syndromes
- Ivermectin & Myelodysplastic syndromes
- Fenbendazole & Myelodysplastic syndromes
- Vitamin C (incl. high-dose) & Myelodysplastic syndromes
About myelodysplastic syndromes
Sources: NCI PDQ, MedlinePlus, The Lancet Oncology
A group of blood cancers in which the bone marrow makes blood cells that do not grow into healthy ones. Too few healthy blood cells can lead to infection, anaemia or easy bleeding. Treatment ranges from blood transfusions and medicines to strong chemotherapy with a stem cell transplant, which can cure some people. It is rare and more likely after age 60, or after chemotherapy or radiotherapy for another cancer.
What is it?
Myelodysplastic syndromes (MDS) are a group of blood cancers. Normally, stem cells in the bone marrow grow into healthy red cells, white cells and platelets. In MDS many of them do not mature and die in the marrow. This leaves too few healthy blood cells, which can lead to anaemia (too few red cells), infections and bleeding.
MDS is rare and mostly affects older people: half are about 70 or older when they find out. In most people the cause is not known. The risk is higher after chemotherapy or radiotherapy for another cancer, and after contact with tobacco smoke, some chemicals (such as benzene, pesticides or fertilisers) or heavy metals such as lead and mercury.
The first signs
MDS often causes no early signs and is sometimes found by a routine blood test.
- feeling weak or tired;
- shortness of breath;
- skin that is paler than usual;
- bruising or bleeding easily, or tiny spots under the skin caused by bleeding;
- fever or infections that keep coming back.
How doctors find out
Blood tests count the red blood cells, white blood cells and platelets. A bone marrow test takes a small sample of marrow with a needle, and a lab checks it for abnormal cells and chromosome changes. Some of these tests, such as checking the chromosomes, help plan treatment.
Current treatment
Treatment depends on several factors. It can include transfusions, medicines that help make red blood cells, and antibiotics for symptoms; lenalidomide or azacitidine and decitabine for some people; and chemotherapy with a donor stem cell transplant for certain patients.
Will it get worse?
Prognosis (chance of recovery) and treatment options depend on certain factors. How it goes depends on how many immature cells (blasts) are in the marrow, how many kinds of blood cells are low, certain chromosome changes, whether it followed earlier cancer treatment, and your age and general health. Some types of MDS can turn into acute myeloid leukaemia (AML).
Medicines: what helps, and what to watch for
Supportive care eases the problems caused by the disease. It can include red blood cell or platelet transfusions, medicines that help the body make more red blood cells, and antibiotics to fight infection. Azacitidine or decitabine can slow the change to AML. Lenalidomide helps some people with a certain chromosome change (del(5q)) need fewer transfusions. People at high risk of AML may get the same chemotherapy as for AML.
Good to know:
- Many transfusions can build up too much iron in the body and harm organs; medicines can remove the extra iron;
- You can join a clinical trial before, during or after treatment, and some trials take only people who have not started treatment.
A transplant, for some people
Some people can be cured with strong chemotherapy followed by a stem cell transplant from a donor, which gives them healthy blood-forming cells. It may not work as well when MDS was caused by earlier cancer treatment.
Is there a cure?
For some people, yes: strong chemotherapy with a donor stem cell transplant can cure certain patients. There is no standard treatment when MDS comes back or stops responding. Clinical trials are testing new treatments.
Median survival
About 2 years with azacitidine, in higher-risk MDS
Measured in: Higher-risk myelodysplastic syndromes: a phase III trial of azacitidine against conventional care (358 patients)
The figures behind it
Phase III trial in higher-risk myelodysplastic syndromes (358 patients): median overall survival 24.5 months with azacitidine vs 15.0 months with conventional care regimens. Lower-risk MDS is not part of this figure.
Sources
Written in plain words by Frontlight from these pages:
- NCI PDQ: Myelodysplastic Syndromes Treatment (PDQ®) – Patient Version
- MedlinePlus: Myelodysplastic Syndromes
- NCI PDQ: Myelodysplastic Syndromes Treatment (PDQ®) – Health Professional Version
- The Lancet Oncology: Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study